These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 18241617)

  • 1. Adipocyte/macrophage fatty acid binding proteins in metabolic syndrome.
    Erbay E; Cao H; Hotamisligil GS
    Curr Atheroscler Rep; 2007 Sep; 9(3):222-9. PubMed ID: 18241617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of metabolic responses by adipocyte/macrophage Fatty Acid-binding proteins in leptin-deficient mice.
    Cao H; Maeda K; Gorgun CZ; Kim HJ; Park SY; Shulman GI; Kim JK; Hotamisligil GS
    Diabetes; 2006 Jul; 55(7):1915-22. PubMed ID: 16804058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes.
    Maeda K; Cao H; Kono K; Gorgun CZ; Furuhashi M; Uysal KT; Cao Q; Atsumi G; Malone H; Krishnan B; Minokoshi Y; Kahn BB; Parker RA; Hotamisligil GS
    Cell Metab; 2005 Feb; 1(2):107-19. PubMed ID: 16054052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice.
    Furuhashi M; Fucho R; Görgün CZ; Tuncman G; Cao H; Hotamisligil GS
    J Clin Invest; 2008 Jul; 118(7):2640-50. PubMed ID: 18551191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis.
    Makowski L; Hotamisligil GS
    Curr Opin Lipidol; 2005 Oct; 16(5):543-8. PubMed ID: 16148539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the fatty acid binding protein mal1 in obesity and insulin resistance.
    Maeda K; Uysal KT; Makowski L; Görgün CZ; Atsumi G; Parker RA; Brüning J; Hertzel AV; Bernlohr DA; Hotamisligil GS
    Diabetes; 2003 Feb; 52(2):300-7. PubMed ID: 12540600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatty Acid-Binding Protein 4 in Cardiovascular and Metabolic Diseases.
    Furuhashi M
    J Atheroscler Thromb; 2019 Mar; 26(3):216-232. PubMed ID: 30726793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets.
    Furuhashi M; Hotamisligil GS
    Nat Rev Drug Discov; 2008 Jun; 7(6):489-503. PubMed ID: 18511927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).
    Wang YT; Liu CH; Zhu HL
    Expert Opin Ther Pat; 2016 Jul; 26(7):767-76. PubMed ID: 27109571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A New Insight into Fatty Acid Binding Protein 4 Mechanisms and Therapeutic Implications in Obesity-Associated Diseases: A Mini Review.
    Başarır Sivri FN; Çiftçi S
    Mol Nutr Food Res; 2024 Apr; 68(8):e2300840. PubMed ID: 38593305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice.
    Boord JB; Maeda K; Makowski L; Babaev VR; Fazio S; Linton MF; Hotamisligil GS
    Circulation; 2004 Sep; 110(11):1492-8. PubMed ID: 15353487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2.
    Furuhashi M; Tuncman G; Görgün CZ; Makowski L; Atsumi G; Vaillancourt E; Kono K; Babaev VR; Fazio S; Linton MF; Sulsky R; Robl JA; Parker RA; Hotamisligil GS
    Nature; 2007 Jun; 447(7147):959-65. PubMed ID: 17554340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophages, inflammation, and atherosclerosis.
    Linton MF; Fazio S
    Int J Obes Relat Metab Disord; 2003 Dec; 27 Suppl 3():S35-40. PubMed ID: 14704742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis.
    Makowski L; Boord JB; Maeda K; Babaev VR; Uysal KT; Morgan MA; Parker RA; Suttles J; Fazio S; Hotamisligil GS; Linton MF
    Nat Med; 2001 Jun; 7(6):699-705. PubMed ID: 11385507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adipocyte Fatty Acid Binding Protein (A-FABP) as a Potential New Therapeutic Target for the Treatment of Obesity - Associated Cancers.
    Majchrzak K; Piotrowska M; Krajewska J; Fichna J
    Curr Drug Targets; 2022; 23(6):597-605. PubMed ID: 34254912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome.
    Xu A; Wang Y; Xu JY; Stejskal D; Tam S; Zhang J; Wat NM; Wong WK; Lam KS
    Clin Chem; 2006 Mar; 52(3):405-13. PubMed ID: 16423904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart and liver fatty acid binding proteins and the metabolic syndrome.
    Binas B
    Curr Hypertens Rep; 2005 Dec; 7(6):401-6. PubMed ID: 16386194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis.
    Boord JB; Fazio S; Linton MF
    Curr Opin Lipidol; 2002 Apr; 13(2):141-7. PubMed ID: 11891416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic functions of FABPs--mechanisms and therapeutic implications.
    Hotamisligil GS; Bernlohr DA
    Nat Rev Endocrinol; 2015 Oct; 11(10):592-605. PubMed ID: 26260145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid chaperones and metabolic inflammation.
    Furuhashi M; Ishimura S; Ota H; Miura T
    Int J Inflam; 2011; 2011():642612. PubMed ID: 22121495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.